Want to see SCYX full AI Analyst Report?
SCYX Stock Chart & Stats
$5.67
-$0.16(-4.29%)
At close: 4:00 PM EDT
$5.67
-$0.16(-4.29%)
Day’s Range― - ―
52-Week Range$3.53 - $9.12
Previous Close$3.57
Volume103.76K
Average Volume (3M)67.16K
Market Cap
$43.68M
Enterprise Value-$4.09
Total Cash (Recent Filing)$54.08M
Total Debt (Recent Filing)$1.95M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Nov 11, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding9,949,609
10 Day Avg. Volume70,380
30 Day Avg. Volume67,163
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.50Price Target Upside208.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.47
Revenue Forecast (FY)$1.25M
Bulls Say, Bears Say
Bulls Say
Low LeverageTTM debt-to-equity of about 0.03 indicates limited financial leverage and preserves flexibility relative to a heavily debt-funded model. The sizable equity base can provide a better cushion for continued development and commercialization while reducing the near-term interest burden.
Antifungal Product PlatformIbrexafungerp’s oral and intravenous formulations address serious fungal infections across multiple treatment settings, giving SCYNEXIS a defined therapeutic platform. A product aimed at important pathogens can support commercialization and licensing opportunities if clinical and market adoption continue.
Experienced LeadershipAdding a director with more than three decades of drug-development experience strengthens governance and may improve strategic oversight as SCYNEXIS advances SCY-770 and its rare-disease plans. His background is relevant to the company’s stated pipeline and long-term therapeutic ambitions.
Bears Say
Persistent LossesThe TTM loss profile shows that SCYNEXIS has not yet established durable profitability despite its antifungal assets. Deeply negative EBIT and EBITDA margins reduce internal funding capacity, increase reliance on financing or partnerships, and make earnings outcomes highly sensitive to execution.
Cash BurnNegative operating and free cash flow mean the business is currently consuming cash rather than self-funding its operations and development work. Continued burn can constrain investment choices and increase the importance of financing, licensing proceeds, or successful commercialization over the next several quarters.
Potential DilutionThe expanded share authorization, larger equity incentive plan, and registered resale capacity create a lasting potential supply of additional shares. If used for compensation, fundraising, or warrant exercises, these measures could dilute existing holders and add complexity to capital allocation.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $3.53 and its highest was $9.12 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $43.68M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Nov 11, 2026 which is in 44 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 10, 2026. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of -$0.507 by $1.137.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.72.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,949,609 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of $0.63 in its last earnings report, beating expectations of -$0.507. Following the earnings report the stock price went down -6.208%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (208.64% Upside)
$17.50 (208.64% Upside)
Blogger Sentiment
Bullish
SCYX Sentiment 100%
Sector Average 64%
Sector Average 64%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
SCYX Stock 12 Month Forecast
Average Price Target
$17.50
▲(208.64% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
24.08% Insiders
19.44% Mutual Funds
42.37% Other Institutional Investors
9.64% Public Companies and
Individual Investors